Lung cancer: who works on it

One card per institution. Pick a target to see only the groups that work on it.

• All targets
• EGFR 300
• PD-L1 162
• PD-1 156
• KRAS 98
• ALK 72
• TP53 10
• HER2 63
• MET 43
• PI3K 1
• STAT3 0
• AKT 2
• ROS1 27
• mTOR 0
• VEGF 23
• BRAF 9
• RET 9
• NRF2 1
• MAPK 1
• ERK 0
• STING 0
• STK11 7
• YAP 1
• DLL3 27
• CTLA-4 15
• RAS 15
• CTNNB1 0
• TROP2 13
• JAK 1
• HIF-1 1
• AMPK 0
• PARP 2
• KEAP1 5
• JNK 0
• MYC 1
• B7-H3 14
• GPX4 0
• HER3 11
• PTEN 4
• MEK 1
• TIGIT 6
• FGFR 3
• IL-6 1
• PPAR 0
• EZH2 2
• HDAC 0
• PRMT5 7
• FAK 0
• COX-2 0
• HMGB1 0
• NTRK 5
• AXL 3
• BCL-2 0
• CDK4/6 4
• CXCR4 1
• CD47 1
• METTL3 0
• NLRP3 0
• SHP2 0
• HSP90 0
• MDM2 1

24 of 62+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Designing Programmable MOF-nanocomposites for Synergistic, Redox-Driven Antitumor Therapies (Photo-bioMOF)

  Fundacion IMDEA Energia· Mostoles Madrid, Spain· EU contribution €262,393· until Feb 2030· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Identifying and disrupting neuroimmune circuits in cancer (NeuroCAN)

  Universitat Basel· Basel, Switzerland· EU contribution €1,874,590· until Jun 2032

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Predicting immunotherapy response in melanoma and non-small cell lung cancer patients using an extracellular vesicle-derived miRNA signature and a non-invasive CRISPR-based detection assay. (IT-PREDICT)

  Centre Georges-Francois Leclerc Association· Dijon, France· EU contribution €242,261· until Mar 2029

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  A Dual Amplification Photoelectrochemical Platform for KRAS Mutation Detection (PEAKRAS)

  Universiteit Antwerpen· Antwerpen, Belgium· EU contribution €216,240· until Jan 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  KRAS Targeting in Oncogenic Systems: reconstructing the KRAS signalling network to identify optimal drug combinations (KRATOS)

  University College Dublin, National University of Ireland, Dublin· Dublin, Ireland· EU contribution €426,534· until Jan 2030· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-SE

  EXPLORING THE MECHANISM OF METASTASIS/DEVELOPMENT OF NEW TESTS TO ENROLL CIRCULATING TUMOR CELLS (CTCs) INTO CLINICAL PRACTICE (CTC4CLINIC)

  Panepistimio Patron· Rio Patras, Greece· EU contribution €796,590· until Dec 2030· 7 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Targeting selenocysteine metabolism as a novel vulnerability in refractory non-small-cell lung cancer (SelenoResist)

  Universitat Wien· Wien, Austria· EU contribution €214,345· until Nov 2028

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Validation of artificial intelligence-based minibinders and inhibitors of Midkine in immune resistant tumours (MDK_MINIBINDERS)

  Fundacion Sector Publico Estatal Centro Nacional Investigaciones Oncologicas Carlos Iii· Madrid, Spain· EU contribution €150,000· until Apr 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Specific delivery of active biomolecules to treat lung cancer (SafeDelivery)

  Fundacio Centre de Regulacio Genomica· Barcelona, Spain· EU contribution €3,323,826· until Oct 2031

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Delivering a '1-2 punch' to RAS-driven cancers (RAS-PUNCH)

  Karolinska Institutet· Stockholm, Sweden· EU contribution €236,340· until Oct 2028

10 of 66 running projects, newest first. Listed amounts together: €224.7m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  PF-07284892 in Participants With Advanced Solid Tumors

  NCT04800822· Pfizer· Updated 4 Jun 2026

  “The study was prematurely discontinued due to strategic reasons. The PF-07284892 program will continue”Registry text, quoted unchanged. Source

• Terminated

  Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)

  NCT04585815· Pfizer· Updated 9 Jan 2026

  “Study was terminated due to portfolio re-prioritization and strategic considerations. The decision was not based on any safety concerns and/or regulatory interactions”Registry text, quoted unchanged. Source

• Terminated

  A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement

  NCT04543188· Pfizer· Updated 23 Oct 2025

  “Pfizer has made an internal business decision to not continue further development of PF-07284890. This decision was not due to major safety concerns or requests from any regulatory authorities.”Registry text, quoted unchanged. Source

• Suspended

  JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

  NCT04418167· JS InnoPharm, LLC· Updated 3 Sept 2025

  “Sponsor decision”Registry text, quoted unchanged. Source

• Terminated

  A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma

  NCT02974725· Novartis Pharmaceuticals· Updated 13 Apr 2025

  “Business reasons”Registry text, quoted unchanged. Source

• Terminated

  A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors

  NCT05501912· ABM Therapeutics Shanghai Company Limited· Updated 29 Nov 2024

  “Adjustment of the applicant's research and development strategy”Registry text, quoted unchanged. Source

• Terminated

  Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors

  NCT04190628· ABM Therapeutics Corporation· Updated 21 May 2024

  “Not related to safety concerns or lack of efficacy”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Dabrafenib and/or Trametinib Rollover Study

  NCT03340506· Novartis Pharmaceuticals· Source

• DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.

  NCT07440290· Cancer Research UK· Source

• ENCOrafenib With Binimetinib in bRAF NSCLC

  NCT04526782· Intergroupe Francophone de Cancerologie Thoracique· Source

• An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer

  NCT03915951· Pfizer· Source

• A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC

  NCT04452877· Novartis Pharmaceuticals· Source

• Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)

  NCT04585815· Pfizer· Source

• DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.

  NCT05768178· Cancer Research UK· Source

• Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

  NCT03944772· AstraZeneca· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 145
• Organoids 47
• Mendelian Randomization Analysis 66
• CRISPR-Cas Systems 43
• Gene Expression Profiling 314
• Sequence Analysis, RNA 43
• Whole Genome Sequencing 13
• Exome Sequencing 18
• Proteomics 133
• Metabolomics 67
• Mass Spectrometry 25
• Flow Cytometry 73
• Immunohistochemistry 191
• Liquid Biopsy 76
• Circulating Tumor DNA 83
• Xenograft Model Antitumor Assays 617
• Positron-Emission Tomography 70
• Magnetic Resonance Imaging 116
• Machine Learning 290
• Deep Learning 211
• Cohort Studies 289
• Genome-Wide Association Study 75

• Integrated Whole-Genome and RNA Sequencing Analysis of FFPE Lung Cancer Samples: Feasibility and Pathological Validation.

  Pathol Int, Nov 2026

• Network-informed deconvolution of bulk immune gene co-expression reveals single-cell programs and spatial organization.

  Front Immunol, Sept 2026

• 5' Rapid Amplification of cDNA Ends (5' RACE)-Based Targeted RNA Sequencing Assay for the Analysis of Clinically Relevant Alterations in Lung Cancer Patients.

  Int J Mol Sci, Aug 2026

• Regulatory effects of smoking cessation on the cellular microenvironment and differentially expressed genes in precancerous lesions of pulmonary nodules in mice based on single-cell RNA sequencing and immune repertoire-sequencing.

  PLoS One, Aug 2026

• DeMixNB: deconvolution of sparse-count RNA sequencing data for tumor cells using embedded negative binomial distributions.

  Genome Biol, Aug 2026

• A Rho GTPase-related gene signature predicts prognosis and reveals an immunosuppressive microenvironment in lung adenocarcinoma: an integrated analysis of bulk and single-cell RNA sequencing data.

  Sci Rep, Jul 2026

• PLNFGL: joint estimation of multi-condition gene networks from single-cell RNA-seq data.

  Bioinformatics, Jul 2026

• Unveiling tumor heterogeneity by single cell RNA-sequencing: From basic considerations to clinical applications.

  Semin Cancer Biol, Jun 2026

• ScQCenrich enables multi-metric quality control for single-cell RNA sequencing.

  Commun Biol, Jun 2026

• Single cell RNA-sequencing meta-analysis identifies the molecular signature of smoking cessation on the human lung.

  Transl Res, Jun 2026

See which targets of this disease your abstract mentions, and go to the people working on them.